| 替罗非班治疗急性冠脉综合征的临床应用进展 |
| |
| 引用本文： | 韩丽. 替罗非班治疗急性冠脉综合征的临床应用进展[J]. 首都医药, 2014, 0(18): 13-15 |
| |
| 作者姓名： | 韩丽 |
| |
| 作者单位： | 天津市泰达国际心血管病医院,300457 |
| |
| 摘 要： | 替罗非班是一种非肽类的血小板糖蛋白Ⅱb/Ⅲa受体的可逆性拮抗剂，其作用机制是通过抑制纤维蛋白原和血小板Ⅱb/Ⅲa受体结合，从而抗血小板聚集、激活以及血栓形成，广泛应用于急性冠脉综合征患者。本文对替罗非班在机型冠脉综合征中的应用价值、疗效及作用机制做一综述。
|
| 关 键 词： | 替罗非班 急性冠脉综合征 应用进展 |
The clinical application progress of Tirofiban in the treatment of acute coronary syndrome |
| |
| Han Li. The clinical application progress of Tirofiban in the treatment of acute coronary syndrome[J]. Capital Medicine, 2014, 0(18): 13-15 |
| |
| Authors: | Han Li |
| |
| Affiliation: | Han Li( Medicine TEDA international cardiovascular hospital, Tianjin (300457) , China) |
| |
| Abstract: | Tirofiban is a synthetic, non-peptide inhibitor acting at glycoprotein （GP） IIb/IIIa receptors in human platelets. It therefore constitutes an anticoagulant, specifically an inhibitor of platelet aggregation. Tirofiban was widely used in acute coronary syndrome. This article reviewed the clinical value, efficacy and mechanism for Tirofiban in the treatment of acute coronary syndrome. |
| |
| Keywords: | tirofiban acute coronary syndrome clinical progress |
| 本文献已被 维普 等数据库收录！ |
